Edition:
India

Pieris Pharmaceuticals Inc (PIRS.OQ)

PIRS.OQ on NASDAQ Stock Exchange Capital Market

5.60USD
13 Jul 2018
Change (% chg)

-- (--)
Prev Close
$5.60
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
157,254
52-wk High
$9.69
52-wk Low
$4.44

Chart for

About

Pieris Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company's pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low... (more)

Overall

Beta: --
Market Cap(Mil.): $276.04
Shares Outstanding(Mil.): 44.31
Dividend: --
Yield (%): --

Financials

BRIEF-Pieris Pharmaceuticals Reports Q1 Loss Per Share $0.17

* PIERIS PHARMACEUTICALS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

10 May 2018

BRIEF-Pieris Pharmaceuticals Prices Public Offering Of 5.50 Mln Common Shares At $8/Share

* PIERIS PHARMACEUTICALS ANNOUNCES PRICING OF ITS PUBLIC OFFERING

14 Feb 2018

BRIEF-Seattle Genetics And Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

* SEATTLE GENETICS AND PIERIS PHARMACEUTICALS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION

09 Feb 2018

BRIEF-Pieris Pharmaceuticals And Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

* PIERIS PHARMACEUTICALS AND SEATTLE GENETICS ANNOUNCE MULTI-PROGRAM IMMUNO-ONCOLOGY COLLABORATION Source text for Eikon: Further company coverage:

09 Feb 2018

Earnings vs. Estimates